Dare Bioscience Inc reports results for the quarter ended June 30 - Earnings Summary

• Dare Bioscience Inc DARE.OQ reported a quarterly adjusted loss of 45 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of $1.52. The mean expectation of four analysts for the quarter was for a loss of 58 cents per share. Wall Street expected results to range from -74 cents to -48 cents per share.

• Revenue rose 195.5% to $-21.00 thousand from a year ago; analysts expected $188.67 thousand.

• Dare Bioscience Inc's reported EPS for the quarter was a loss of 45 cents​.

• The company reported a quarterly loss of $4 million.

• Dare Bioscience Inc shares had fallen by 11.7% this quarter and lost 32.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 36.5% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Dare Bioscience Inc is $13.00, about 83.8% above its last closing price of $2.11

This summary was machine generated from LSEG data August 14 at 09:00 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)